Table 1.
Baseline clinical and demographic characteristics of patients.
| None (N = 513) | mPARPi (N = 160) | Total (N = 673) | P value | |
|---|---|---|---|---|
| Year of therapy initiation | < 0.001 | |||
| 2015 to 2017 | 285 (55.6%) | 11 (6.8%) | 296 (43.9%) | |
| 2018 | 88 (17.2%) | 12 (7.5%) | 100 (14.9%) | |
| 2019 | 70 (13.6%) | 34 (21.2%) | 104 (15.5%) | |
| 2020 | 35 (6.8%) | 47 (29.4%) | 82 (12.2%) | |
| 2021 | 29 (5.7%) | 40 (25.0%) | 69 (10.3%) | |
| 2022 | 6 (1.2%) | 16 (10.0%) | 22 (3.3%) | |
| Ancestry | 0.283 | |||
| AFR | 40 (7.8%) | 7 (4.4%) | 47 (7.0%) | |
| AMR | 37 (7.2%) | 12 (7.5%) | 49 (7.3%) | |
| EAS | 12 (2.3%) | 8 (5.0%) | 20 (3.0%) | |
| EUR | 416 (81.1%) | 130 (81.2%) | 546 (81.1%) | |
| SAS | 8 (1.6%) | 3 (1.9%) | 11 (1.6%) | |
| Age | 0.661 | |||
| Median (Q1 and Q3) | 67.0 (58.0, 74.0) | 66.0 (60.8, 73.0) | 67.0 (59.0, 73.0) | |
| Practice type | 0.333 | |||
| Academic | 135 (26.3%) | 36 (22.5%) | 171 (25.4%) | |
| Community | 378 (73.7%) | 124 (77.5%) | 502 (74.6%) | |
| ECOG | 0.882 | |||
| 0 | 195 (38.0%) | 57 (35.6%) | 252 (37.4%) | |
| 1 | 176 (34.3%) | 58 (36.2%) | 234 (34.8%) | |
| 2+ | 41 (8.0%) | 11 (6.9%) | 52 (7.7%) | |
| Unknown | 101 (19.7%) | 34 (21.2%) | 135 (20.1%) | |
| BMI | 0.569 | |||
| Median (Q1, Q3) | 26.8 (22.4, 30.8) | 26.0 (22.0, 31.1) | 26.6 (22.3, 30.8) | |
| N-miss | 13 | 1 | 14 | |
| Stage at diagnosis | 0.043 | |||
| Stage III | 335 (65.3%) | 93 (58.1%) | 428 (63.6%) | |
| Stage IV | 108 (21.1%) | 49 (30.6%) | 157 (23.3%) | |
| Unknown/not documented | 70 (13.6%) | 18 (11.2%) | 88 (13.1%) | |
| Histology | 0.156 | |||
| Epithelial NOS | 35 (8.9%) | 15 (13.4%) | 50 (9.9%) | |
| Serous | 360 (91.1%) | 97 (86.6%) | 457 (90.1%) | |
| Extent of debulking | 0.149 | |||
| Optimal | 371 (72.3%) | 116 (72.5%) | 487 (72.4%) | |
| Suboptimal | 36 (7.0%) | 5 (3.1%) | 41 (6.1%) | |
| Unknown/not documented | 106 (20.7%) | 39 (24.4%) | 145 (21.5%) | |
| Residual disease status | 0.307 | |||
| No residual disease | 239 (46.6%) | 82 (51.2%) | 321 (47.7%) | |
| Residual disease | 147 (28.7%) | 36 (22.5%) | 183 (27.2%) | |
| Unknown/not documented | 127 (24.8%) | 42 (26.2%) | 169 (25.1%) | |
| TP53 alteration | 0.039 | |||
| Wild-type | 40 (7.8%) | 5 (3.1%) | 45 (6.7%) | |
| Positive | 473 (92.2%) | 155 (96.9%) | 628 (93.3%) | |
| BRCA group | <0.001 | |||
| BRCA1 | 52 (10.1%) | 29 (18.1%) | 81 (12.0%) | |
| BRCA2 | 28 (5.5%) | 21 (13.1%) | 49 (7.3%) | |
| Wild-type | 433 (84.4%) | 110 (68.8%) | 543 (80.7%) | |
| gLOH-high level | <0.001 | |||
| High | 136 (35.5%) | 75 (59.5%) | 211 (41.5%) | |
| Low | 247 (64.5%) | 51 (40.5%) | 298 (58.5%) | |
| N-miss | 130 | 34 | 164 | |
| HRDsig | <0.001 | |||
| (+) | 175 (34.1%) | 83 (51.9%) | 258 (38.3%) | |
| (−) | 338 (65.9%) | 77 (48.1%) | 415 (61.7%) | |
| Time of tissue collection | <0.001 | |||
| Before platinum therapy initiation | 0 (0.0%) | 11 (6.9%) | 11 (1.6%) | |
| After platinum therapy initiation | 260 (50.7%) | 42 (26.2%) | 302 (44.9%) | |
| After maintenance initiation | 253 (49.3%) | 107 (66.9%) | 360 (53.5%) | |
| PARPi used | — | |||
| Niraparib | — | 76 (47.5%) | 76 (47.5%) | |
| Olaparib | — | 55 (34.4%) | 55 (34.4%) | |
| Rucaparib | — | 13 (8.1%) | 13 (8.1%) | |
| Niraparib and olaparib | — | 10 (6.3%) | 10 (6.3%) | |
| Olaparib and rucaparib | — | 4 2.5%) | 4 2.5%) | |
| Niraparib, olaparib, and rucaparib | — | 2 (1.3%) | 2 (1.3%) | |
Abbreviations: AFR; African, AMR; admixed American, BMI; body mass index, chemo; chemotherapy, ECOG; Eastern Cooperative Oncology Group performance status, EAS; East Asian, EUR; European, NOS; not otherwise specified, SAS; South Asian,